About Us
Candesant Biomedical
Candesant Biomedical is a clinical stage company focused on development of a novel treatment for the non-invasive treatment of excessive sweating or hyperhidrosis.
The company’s lead investigational product is a topical patch to conveniently treat excessive sweating with a quick, in-office procedure.
Two successful clinical studies demonstrated efficacy in reducing sweat and validated that the energy is reproducibly generated, highly targeted and appears to inactivate the most active sweat glands.
In these initial clinical studies, Candesant’s investigational treatment demonstrated significant sweat reduction benefits lasting up to 2 months after a single, no down-time treatment.
Leadership
Candesant is led by a deeply experienced team of drug and device development professionals passionate about meeting real patient and physician needs.
Niquette Hunt
Founder and CEO
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products.
Niquette Hunt
Founder and CEO
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing.
Mary Beth Kreissler
Chief Financial Officer
Mary Beth has 20 years’ experience with pre-revenue and early commercialization stage companies in tech and life sciences.
Mary Beth Kreissler
Chief Financial Officer
Mary Beth has 20 years’ experience with pre-revenue and early commercialization stage companies in tech and life sciences. She previously helped launch and lead finance for Willow Pump, SmartThings, Qatalyst Partners and Quinstreet. She began her career with PricewaterhouseCoopers.
Angela Boyd
Chief Commercial Officer
Angela has more than 25 years experience developing and launching products in the dermatology/aesthetics space.
Angela Boyd
Chief Commerical Officer
Angela has more than 25 years experience developing and launching products in the dermatology/aesthetics space.
Erica Bazerkanian
SVP Marketing
Erica Bazerkanian has 25 years’ experience in commercial strategy, new product development and market creation.
Erica Bazerkanian
SVP Marketing
Erica Bazerkanian has 25 years’ experience in commercial strategy, new product development and market creation, including 15 years in medical aesthetics at companies such as Kythera Biopharmaceuticals and Revance Therapeutics. Most recently she served as vice president, aesthetics and therapeutics marketing for Revance Therapeutics, leading pre-commercialization efforts for the company’s aesthetic and therapeutic botulinum toxin portfolio.
Jesse Rosen
VP Product Development
Jesse has 20+ years of experience in the design, development and manufacturing of medical devices.
Jesse Rosen
VP Product Development
Jesse has 20+ years of experience in the design, development and manufacturing of medical devices. He was an early employee at Zeltiq as well as head of product development at Myoscience.
Erin Tims
VP Clinical Affairs
Erin has 15 years experience in the design and execution of clinical studies across various therapeutic categories.
Erin Tims
VP Clinical Affairs
Erin has 15 years experience in the design and execution of clinical studies across various therapeutic categories. She has successfully overseen the regulatory approval process for both multi-national corporations and start-ups.
Antwan Gipson
VP Manufacturing & Operations
Antwan has over 20 years of experience in manufacturing, engineering, and operations across all stages of life science companies.
Antwan Gipson
VP Manufacturing & Operations
Antwan has over 20 years of experience in manufacturing, engineering, and operations across all stages of life science companies, including executive roles in aesthetics, pharmaceuticals, biologics, and medical devices. He has worked with J&J, Allergan and most recently Tautona Group helping to exit several portfolio products worldwide.
Scott Wilson
Head, Regulatory Affairs
Scott has over 25 years' experience in the medical device industry, specializing in regulatory affairs and quality.
Scott Wilson
Head, Regulatory Affairs
Scott has over 25 years' experience in the medical device industry, specializing in regulatory affairs and quality. He has contributed to the success of both venture funded and commercial stage companies developing novel therapies.
In Remembrance
Jacob Waugh, MD
Co-Founder, Inventor of the TAT Technology
Jacob Waugh, a prolific inventor who left behind 40+ issued and 300+ pending patents, dedicated his life to scientific innovation and development.
Jacob Waugh, MD
Co-Founder, Inventor of the TAT Technology
Jacob Waugh dedicated his life to scientific innovation and development. He was a gifted physician, scientist, entrepreneur and educator. Jacob was a pioneer in in-vivo tissue engineering at Stanford Medical Center. Prior to Candesant, he was the co-founder, chief scientific officer and medical director of Revance Therapeutics. He was a prolific inventor and leaves behind 40+ issued and 300+ pending patents. He will be deeply missed.
Board of Directors
Samara Braunstein
Samara Braunstein is a marketing and financial professional with decades of experience in healthcare, consumer products, and finance.
Samara Braunstein
Sam’s extensive industry knowledge stems from past roles in the M&A group at Credit Suisse, as a deal professional at GTCR, and as a senior member of portfolio companies for Lightyear Capital and The Carlyle Group. Sam also served on the Board of Directors for Higher One Holdings (NYSE:ONE) through its acquisition by a Providence Equity subsidiary. She served until recently as the Chief Revenue Officer of Concertiv, which provides outsourced operations and technologies to over 50 financial institutions.
Sam leverages her diverse experience in sales and marketing gained from her work as Director of Interactive marketing at AOL and from her work in brand management at Pfizer (Warner Lambert), where she worked on initiatives such as the launch of Zantac 75 OTC, which generated more than $150 million in year one sales. Sam was CEO and founder of Wellgate Products and led the company to #4 market share in the U.S. prior to its acquisition by Church & Dwight Co., Inc.
Michael Kane, MD
Michael Kane, MD is an aesthetic plastic surgeon and entrepreneur who has been practicing in New York City for more than 25 years.
Michael Kane, MD
Michael is an aesthetic plastic surgeon and entrepreneur who has been practicing in New York City for more than 25 years. Dr. Kane performs a wide variety of cutting-edge cosmetic surgical procedures, facial rejuvenation, and cosmetic injections. Dr. Kane has been in private practice since 1992 and frequently lectures on topics relating to aesthetic plastic surgery and aesthetic medicine. Dr. Kane completed his college and medical school studies in only five years at the combined Pennsylvania State University/Jefferson Medical College program. At Jefferson, Dr. Kane was a member of the Hobart Hare Honor Society. Dr. Kane completed a general surgery residency at New York Medical College and then a plastic surgical residency at Wright State University, Dr. Kane then completed an additional fellowship in aesthetic surgery at New York University, based at the Manhattan Eye, Ear & Throat Hospital. Dr. Kane is known for his work with botulinum toxin A. He pioneered the use of Botulinum for cosmetic purposes while a fellow at the Manhattan Eye, Ear & Throat Hospital. Over the past 25 years, Dr. Kane has taught thousands of physicians how to properly inject botulinum toxin and fillers through lectures and live demonstrations. Dr. Kane is also an authority on correcting the tear trough and periorbital area using fillers. He authored the first scientific paper on this technique, and continues to lecture worldwide on the subject. Dr. Kane has over one thousand scientific presentations around the globe. His original work has appeared in Plastic and Reconstructive Surgery, the Aesthetic Surgery Journal, Aesthetic Plastic Surgery, Dermatologic Surgery, the Journal of Drugs in Dermatology, the Journal of Cosmetic Laser Therapy, Facial Plastic Surgery, and Ophthalmic Plastic and Reconstructive Surgery. He launched the award-winning Serum Savant skin care line in 2015. He serves as a consultant to nearly all of the major aesthetics companies. He has written many textbook chapters and three books.
Karen Long
Karen Long is a Managing Director of KCK MedTech and an experienced operating executive with over 20 years’ experience
Karen Long
Karen is a Managing Director at KCK Medical Technologies, which focuses capital investment on commercial and growth-stage medical device companies. She serves as a Board Director on multiple KCK portfolio companies. Additionally, she holds several independent Board Director positions.
Karen has spent more than 20 years in medical devices and diagnostics, developing and marketing novel, market-leading products focused on improving quality of life. Prior to KCK, Karen was President and CEO of Nuelle, a women’s consumer health company. She has held a series of key management roles in consumer health companies, including ChemTrak, Inverness Medical, and LifeScan. In 2007, she joined Acclarent, Inc. as World Wide Vice President of Marketing, where she helped spearhead rapid growth leading to the company’s 2010 acquisition by Johnson & Johnson.
Karen began her career as a Licensed Clinical Social Worker after receiving her undergraduate and graduate degrees from San Diego State University.
Ellie McGuire
Ellie McGuire is a partner of the LS Polaris Innovation Fund. McGuire currently serves on the Boards of Montis Biosciences and Mellitus.
Ellie McGuire
Ellie McGuire is a partner of the LS Polaris Innovation Fund. McGuire currently serves on the Boards of Montis Biosciences and Mellitus. In addition she was the founding President of Volastra Therapeutics and currently acts as CEO of Boston based Mellitus. She is an expert in residence for the Harvard Office of Technology Development and is on the Fred Hutch Evergreen Fund Advisory Committee. Prior to co-founding the LS Polaris Innovation Fund, McGuire was the Head of Business Development at Lyndra, where she was a member of the founding team. She previously held leadership and consulting positions in business development, operations, and strategy in multiple life science companies including Arsia Therapeutics, Lyndra, and XTuit Pharmaceuticals.
Brad Hauser
Brad Hauser is a seasoned aesthetics leader with experience managing R&D, operations and commercial teams.
Brad Hauser
Chief Product Officer for the Beauty Health Company
Brad Hauser is a seasoned aesthetics leader with experience managing R&D, operations and commercial teams. Over the last 20 years, he has assisted in the development and launch of many of the most well-known brands in the aesthetic device industry and successfully transacted and integrated several businesses into both small and large companies. He is currently Chief Product Officer at the Beauty Health Company (Nasdaq: SKIN). Previously, Brad led Soliton, Inc. (Nasdaq: SOLY), as President and CEO, from a clinical-stage start-up through FDA clearance and acquisition by Allergan Aesthetics, an AbbVie company, for $550M enterprise value in 2021. Prior to Soliton, he helped build the CoolSculpting franchise, within Zeltiq Aesthetics, from a $100M to over $350M+ global business over 4 years and sale to Allergan for $2.4B in 2017. He graduated from Stanford University with a degree in Human Biology and concentration in sports medicine.